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Background and Purpose: Thromboxane A2 (TXA2) receptors (TP) interact with the
ligand TXA2 to induce platelet aggregation and regulate hemostasis. Recently TP-
mediated signaling has been suggested to function in multiple cell types in the brain.
In this report, we aim to study the expression and physiological role of TP in microglia,
in particular after brain ischemia.
Methods: Ischemic brain sections were analyzed for TP expression. Microglial cell line
and primary microglia were cultured, or neuronal cell line co-culture system was used to
determine the TP mediated signaling in inflammation and microglia activation.
Results: We found that the TP level was significantly increased in ipsilateral mouse
brain tissue at 24 h after ischemia-reperfusion, which was also found to partly co-
localize with CD11b, a marker for microglial and infiltrated monocyte/macrophage, in
peri-infarct area. Immunofluorescence staining of primary microglia and microglial cell
line BV2 revealed the predominant membrane distribution of TP. Conditioned culture
media from TP agonist U46619-treated BV2 cells decreased neuronal SH-SY5Y cell
viability and induced apoptotic morphological changes. Furthermore, U46619 enhanced
IL-1β, IL-6, and iNOS mRNA expression as well as IL-1β and NO releases in BV2
cells or primary microglia. Such stimulation could be attenuated by TP antagonist
SQ29548 or MEK inhibitor U0126. The dose- and time-dependent extracellular-signal-
regulated kinase (ERK) phosphorylation induced by U46619 further demonstrated ERK
signaling-mediated microglia activation by TP agonist.
Conclusion: This study has shown a novel role of TP in microglia activation via the ERK
signaling pathway, which provides insights for the management of neuroinflammation in
diseases like cerebral infarction.
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INTRODUCTION
Cerebral infarction (CI), which accounts for 88% of all strokes,
is an irreversible brain injury resulting from a disturbance
in blood supply to cerebral tissue, characterized by high
morbidity, disability, and mortality rate (Moskowitz et al., 2010).
There is increasing evidence that post-ischemic inﬂammation
plays an important role in ischemia brain injury (Ceulemans
et al., 2010). Microglia are the resident macrophages in central
nervous system, which plays a critical role in the post-
ischemic inﬂammation of brain ischemia (Kawabori and Yenari,
2014). Overly activated microglia will release pro-inﬂammatory
cytokines, chemokines, reactive oxygen species, and nitric oxide
(NO), leading to more severe brain damage (Lai and Todd,
2006).
Thromboxane A2 (TXA2) is an arachidonic acid metabolite
synthesized by cyclooxygenase and thromboxane synthase
(Hamberg et al., 1975). Its chemical half-life is ∼30 s and
it is rapidly degraded into an inactive form of thromboxane
B2 (TXB2). Therefore, TXA2 regulates the functions of cells
around the TXA2-producing cells by an autocrine or paracrine
manner (Nakahata, 2008). Experimental and clinical studies
have demonstrated that there is a local increase of TXA2
biosynthesis in CI (Nusing and Ullrich, 1990; Fisher, 1993).
Activated microglia are the principal source of brain-derived
TXA2 (Giulian et al., 1996). TXA2 exerts its action by binding
to the speciﬁc G protein-coupled TP (Hirata et al., 1991).
In the brain, many types of cells express the TP, such as
microglia (Kitanaka et al., 1995), astrocytes (Nakahata et al.,
1995), and oligodendrocytes (Blackman et al., 1998). The
distribution of the TP in the brain indicates that it may be
involved in a wide range of central nervous system diseases.
Previous studies have shown that gene polymorphism of the
TP is associated with CI (Kaneko et al., 2006; Zhao et al.,
2013; Wang et al., 2014). Under pathological conditions, such
as subarachnoid hemorrhage, the TP level is up-regulated in
the brain (Ansar et al., 2010). Furthermore, stimulation of
the TP in astrocytes resulted in secretion of interleukin 6
(IL-6; Obara et al., 2005). In oligodendrocytes, the TP was
involved in enhanced proliferation and survival (Blackman
et al., 1998; Lin et al., 2005; Ramamurthy et al., 2006).
In Schwann cells, TP activation promotes cyclic adenosine
monophosphate (cAMP) and cAMP-response-element-binding
protein (CREB) phosphorylation (Muja et al., 2001). However,
the physiological function of TXA2 signaling in microglia has not
been investigated.
The objective of this study is to examine the role of TP in
the regulation of microglia inﬂammation and related mechanism,
thus providing new insights for the prevention and treatment of
CI.
MATERIALS AND METHODS
Reagents and Animals
Thromboxane A2 receptors agonist U46619 and antagonist
SQ29548 were purchased from Sigma Aldrich (St. Louis,
MO, USA). MEK inhibitor U0126 was from Cell Signaling
(Beverly, MA, USA). Anti-phospho-ERK antibody and anti-
ERK1/2 antibody were from Cell Signaling (Beverly, MA, USA).
Anti-CD11b antibody was from BD Biosciences (San Jose, CA,
USA). TP antibody was from Santa Cruz Biotechnology (Santa
Cruz, CA, USA). Iba1 antibody was from BD Biosciences (San
Jose, CA, USA). The Cell Counting kit-8 (CCK-8) was from
KeyGen Biotech Co., Ltd. (Nanjing, China). NO assay kit was
from Beyotime Institute of Biotechnology (Haimen, China).
Adult male ICR mice and 24 h neonatal Sprague–Dawley (SD)
rats were purchased from Shanghai SLAC Laboratory Animal
Corporation (Shanghai, China). All animal procedures were
carried out strictly within national guidelines and approved by
the Institutional Animal Care and Use Committee of Shanghai
Jiao Tong University.
Cell Culture
The microglia cell line BV2 and human neuroblastoma cell
line SH-SY5Y were provided by Institute of Neurology, Rui
Jin Hospital (Shanghai, China). BV2 cells were cultured in
Dulbecco’s modiﬁed Eagle’s medium (DMEM) supplemented
with 10% heat-inactivated (56◦C, 30 min) fetal bovine serum
(GIBCO), 1% penicillin/streptomycin (GIBCO). SH-SY5Y cells
were grown in DMEM supplemented with 10% fetal bovine
serum, 1% penicillin/streptomycin. Cells were maintained in
a 5% CO2 humidiﬁed incubator at 37◦C. Primary microglia
and astrocytes were prepared from 24 h neonatal SD rat
brains and then cultivated in DMEM/F12 supplemented
with 10% fetal calf serum, penicillin, and streptomycin, as
previously described (Jana et al., 2007; Tamashiro et al.,
2012).
Real-Time PCR
Total RNA from BV2 cells was extracted by using Trizol Reagent
(Invitrogen, Carlsbad, CA, USA). Reverse transcription of RNA
to cDNA was carried out using a PrimeScript RT reagent kit
(TaKaRa). Quantitative real-time PCR was performed with SYBR
Premix Ex Taq (TaKaRa). Primers had the following sequences:
IL-1β (sense 5′-gcaactgttcctgaactcaact-3′ and anti-sense 5′-
atcttttggggcgtcaact-3′); IL-6 (sense 5′-tagtccttcctaccccaatttcc-3′
and anti-sense 5′-ttggtccttagccactccttc-3′ ); iNOS (sense 5′-
atgtccgaagcaaacatcac-3′ and anti-sense 5′-taatgtccaggaagtaggtg-
3′); GAPDH (sense 5′-aggtcggtgtgaacggatttg-3′ and anti-sense
5′-tgtagaccatgtagttgaggtca-3′). PCR was carried out as follows:
denaturing at 95◦C for 10 seconds, the following 40 cycles of
95◦C for 5 s and 60◦C for 30 s. Data were analyzed by using the
comparative threshold cycle (Ct) method, where Ct is the number
of PCR cycles performed in one sample at a speciﬁc point of time,
and the results were expressed as fold diﬀerence normalized to
GAPDH.
Enzyme-Linked Immunosorbent Assay
(ELISA)
IL-1β ELISA was performed following the protocol of ELISA Kit
(eBioscience). In brief, BV2 cells were seeded to 12-wellplates and
cultured overnight in DMEM without fetal bovine serum. The
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cells were cultured for 24 h in the presence of U46619, and then
the conditioned media were collected, centrifuged at 3000 rpm
for 10 min, and the supernatant was subjected to ELISA. The
absorbance at 450 nm was measured by using a microplate reader
(Synergy2, BioTek). The IL-1β concentration in the conditioned
media was calculated using the standard and normalized against
the total protein concentration of the same sample.
Analysis of Cell Viability
The cell viability was determined by CCK-8 kit according
to the manufacture’s instructions (Liu et al., 2013). BV2
cells were plated into 6-well plates and incubated for
24 h in the presence of U46619, and then the cell-free
BV2 conditioned media were collected, which was applied
to neuronal SH-SY5Y cells that had been seeded in 96-
well plates. After 24 h, CCK-8 was used to evaluate the
changes in SH-SY5Y cell viability. Subsequently, 2 h prior
to measuring the absorbance, 10 μl CCK-8 solution in
90 μl growth medium was added to each well. The optical
density was determined at an absorbance of 450 nm using a
microplate reader (Synergy2, BioTek). Morphological change
of SH-SY5Y cell was examined under the phase-contrast
microscopy.
Western Blotting
Western analysis was performed as described previously (Xie
et al., 2013). Cells were lysed in RIPA buﬀer (Millipore,
Temecula, CA, USA) containing Complete Protease Inhibitor
Cocktail, Phosphatase Inhibitor Cocktail and 2 mM PMSF.
Thirty microgram of total protein was electrophoresed through
a 10% SDS-polyacrylamide gel electrophoresis. Proteins were
transferred electrically from the gel onto a 0.45 μmnitrocellulose
membrane (Millipore, Temecula, CA, USA) by the semidry
electro-transfer method. The membranes were blocked for 1 h
with 5% skim milk and incubated with primary antibodies at 4◦C
overnight (anti-phospho-ERK antibody and anti-ERK antibody).
The blots were washed several times and then incubated at room
temperature for 1 h with HRP-conjugated secondary antibody
(1:5000 dilution, Epitomics, China). Finally, protein signals were
visualized using an ECL detection system (Thermo Scientiﬁc).
The densities of the bands were analyzed by densitometry
using a Gel-Pro Analyzer (Media Cybernetics, Bethesda, MD,
USA).
Transient Middle Cerebral Artery
Occlusion (tMCAO) Model
Adult male ICR mice were randomly assigned to the tMCAO
group and sham group. Transient MCAO model in mice
was performed as previously described (Yang et al., 1994;
Liu et al., 2014). Brieﬂy, adult male ICR mice weighing
25–30 g were anesthetized with ketamine (100 mg/kg) and
xylazine (10 mg/kg) intraperitoneally. Then the surgical
procedure of tMCAO was performed as follows: 6-O suture
(Dermalon, 1741-11, Covidien, Cincinnati, OH, USA) coated
with silicone was inserted from the left external carotid
artery into the internal carotid artery and reached to the
origin of middle cerebral artery. With the help of laser
Doppler ﬂowmeter (Moor Instruments, Devon, England),
successful occlusion was characterized as a reduction of cerebral
blood ﬂow (CBF) down to 10% of baseline. After 1.5 h,
the suture was removed for reperfusion. Sham operation
group (n = 5) underwent the same procedure except
suture insertion. All of the animals were sacriﬁced 24 h
after reperfusion.
Immunohistological Staining
Brain cryosections (20 μm in thickness) were ﬁxed for about
10 min with ice-cold 4% paraformaldehyde and thereafter
rehydrated in phosphate buﬀered-saline (PBS, pH 7.2) for
3 × 5 min. The cryosections were then blocked with
10% normal donkey serum and incubated overnight at 4◦C
with the following primary antibodies: mouse anti-CD11b
antibody (1:100 dilution); rabbit anti-TP antibody (1:150
dilution). Subsequently, cryosections were washed with PBS
for 3 × 10 min and incubated with Alexa-488-conjugated
or Alexa-594-conjugated secondary antibody (1:200 dilution,
Life Technologies) for 1 h at room temperature. After
nuclei were stained with 4, 6-diamidino-2-phenylindole (DAPI;
1:500 dilution, Beyotime Institute of Biotechnology, China),
the ﬂuorescence images were acquired using a ﬂuorescence
microscope (Leica, Germany). BV2 cells and Primary microglia
cells were ﬁxed with 4% paraformaldehyde and stained with anti-
TP antibody (1:150 dilution) and Iba1 antibody (1:100 dilution)
at 4◦C overnight, followed by incubation with the ﬂuorescent-
conjugated secondary antibody.
Statistical Analysis
GraphPad Prism6 statistical software was used for statistical
analysis in this study. When multiple groups were compared,
data from three or more independent experiments were
analyzed using one-way ANOVA and Tukey’s post-test
for multiple comparison. All data were expressed as
mean values ± SEM. P < 0.05 was considered statistically
signiﬁcant.
RESULTS
Increased Expression of the TP After
Ischemia-Reperfusion Injury
In order to ascertain whether ischemia-reperfusion enhanced
TP expression, we analyzed brain tissues (striatum) from
mice that underwent tMCAO. TP protein was signiﬁcantly
increased in the injured ipsilateral brain tissue compared
with contralateral hemisphere of the same animal, or with
the sham at 24 h after ischemia-reperfusion (Figures 1A,B).
To further determine the expression of TP in the brain, we
performed TP immunoﬂuorescence staining in the mouse
brain sections and the result showed that the CD11b signal, a
marker for microglial and inﬁltrated monocyte/macrophage
(Akiyama and McGeer, 1990; Mazzone and Ricevuti, 1995),
was remarkably up-regulated in the peri-infarct zone of
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FIGURE 1 | Expression of the Thromboxane A2 receptors (TP) increases in the mouse brain at 24 h after ischemia-reperfusion. (A) Protein levels of the
TP in sham and transient middle cerebral artery occlusion (tMCAO) group at 24 h after ischemia-reperfusion were determined by Western blot, which were quantified
in the Bar chart (bottom). Ipsi, damaged hemisphere; Contra, undamaged hemisphere. Five mice per group. Data were normalized against protein level of the sham
group. Data were presented as mean ± SEM. (B) Protein levels of the TP in ipsilateral and contralateral hemisphere of tMCAO group at 24 h after
ischemia-reperfusion from three different animals were analyzed by Western blot and quantified as in the Bar chart (bottom). Data were normalized against protein
level of the contralateral hemisphere. Data were presented as mean ± SEM, n = 3. (C) Immunofluorescence staining of CD11b and TP together with nuclei (DAPI) in
the striatum of the ipsilateral and contralateral hemisphere. Bar = 100 μm. Five mice per group. (∗∗P < 0.01, ∗∗∗P < 0.001, by one-way ANOVA followed by post
hoc Tukey’s test).
ipsilateral hemisphere at 24 h after ischemia-reperfusion
compared with that in contralateral hemisphere or the
sham (Figure 1C). Furthermore, there was also an up-
regulation of TP signals in the penumbra of ipsilateral
side that mostly appeared to be co-localized with CD11b,
suggesting that at least the activated microglia and inﬁltrated
monocyte/macrophage might contribute signiﬁcantly
to the increase of TP levels after ischemia-reperfusion
(Figure 1C).
Microglial TP Localized Primarily on the
Cytoplasmic Membrane
Previous reports have demonstrated TP was localized in
the plasma membrane and perinuclear compartments in
oligodendrocytes (Ramamurthy et al., 2006). However, the
cellular distribution of the TP in microglia cells is presently
unknown. To determine whether primary microglia and BV2
cells expressed TP and their distribution, immunoﬂuorescence
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FIGURE 2 | Cell surface localization of the TP in microglia cells. Immunofluorescence staining of the TP together with microglia marker Iba-1 in primary
microglia cells (A) and BV2 cells (B). Bar = 50 μm.
FIGURE 3 | BV2 conditioned medium by U46619 treatment induces neurotoxicity in SH-SY5Y cells. (A) The experimental design and procedure. First, BV2
cells were treated by U46619 (10 μM) for 24 h with or without SQ29548 (1 μM, 30 min) pretreatment, and the conditioned medium was collected, which was then
applied to SH-SY5Y cells and incubated for 24 h. Effects on SH-SY5Y cells were assessed either by CCK-8 viability assay or microscopy. (B) The cell viability of
SH-SY5Y cells in various treatment groups was analyzed by CCK-8 assay (Data were normalized against the vehicle-treated group. The data are expressed as the
mean ± SEM. ∗P < 0.05, by one-way ANOVA followed by post hoc Turkey’s test). (C) Representative microscopic photographs of SH-SY5Y cells in various
treatment groups as in (B) were shown. Note the differences between the rounded cell shape in the U46619 group and the long stretched cell shape in other three
groups. Bar = 100 μm.
staining was performed. Primary microglia were stained
positively for the microglia marker Iba-1, conﬁrming their
identity (Figure 2A). The TP was primarily localized on
the cytoplasmic membrane, and also in the perinuclear
compartments of the cytosol in primary microglia (Figure 2A).
In BV2 cells, similar staining pattern was observed, where
TP was detected predominantly on the cytoplasmic membrane
(Figure 2B). These results indicated that both primary microglia
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FIGURE 4 | U46619 enhances proinflammatory cytokines (IL-1β, IL-6) and NO production in BV2 cells. (A) Relative expression of IL-1β mRNA after U46619
or SQ29548 treatment measured by qRT-PCR. (B) Relative expression of IL-6 mRNA under the same conditions. (C) Relative expression of iNOS mRNA under the
same conditions. (D) Relative IL-1β secretion from BV2 cells. After incubation with the indicated concentrations of U46619 for 24 h, IL-1β released from BV2 cells
was measured by ELISA. (E) Relative NO release from BV2 cells after U46619 or SQ29548 treatment (Data were normalized against the vehicle-treated group. Data
were presented as mean ± SEM. ∗P < 0.05, ∗∗P < 0.01 by one-way ANOVA followed by post hoc Tukey’s test).
and BV2 cells expressed TP, which were primarily localized on the
cytoplasmic membrane.
BV2 Microglia After TP Activation
Induced Neurotoxicity in Neuronal
SH-SY5Y Cells
The up-regulation of the TP after ischemic stroke and its
expression in the microglia prompted us to examine the
eﬀects of modulation of TP-mediated signaling. We designed
the following experiments to test such eﬀects on neuronal
cells (Figure 3A). Conditioned medium from BV2 cells
treated with TP agonist U46619 should contain secreted
proteins and other molecules after activation of TP signaling.
A neuronal cell line, human neuroblastoma SH-SY5Y was
used to mimic neurons. Such cell line based co-culture
experiments are helpful in answering basic questions regarding
microglia-neuron interactions (Nam et al., 2013; Zhu et al.,
2014). BV2 cells were treated with U46619 (10 μM) for
24 h with or without the TP antagonist SQ29548 (1 μM)
pretreatment for 30 min, and the conditioned medium was
collected. Then SH-SY5Y cells were incubated with such
conditioned medium for 24 h. Finally, the SH-SY5Y cell
viability was analyzed. Conditioned medium from U46619-
treated BV2 decreased SH-SY5Y cell viability, which was
statistically signiﬁcant compared with vehicle, SQ29548 alone or
U46619 plus SQ29548 group (Figure 3B). To accompany such
ﬁndings, cell morphology was directly observed (Figure 3C).
In all other groups SH-SY5Y cells displayed long processes
whereas in the U46619-treated group some neuronal cells
were induced to show rounded shapes indicative of cell
death (Figure 3C). These results suggested that U46619-
mediated conditioned medium from BV2 might contain
certain factors to reduce SH-SY5Y cell viability. To rule
out the possibility that reagents brought with conditioned
medium might inﬂuence SH-SY5Y cell survival rate, U46619
and SQ29548 were directly added to DMEM medium and
placed in incubator for 24 h, and then those mediums were
applied to neuronal SH-SY5Y cells. CCK-8 assay showed
that there was no statistically signiﬁcance among groups
(Supplementary Figure S1). It suggested that reagents brought
with conditioned medium did not inﬂuence SH-SY5Y cell
survival rate.
U46619 Enhanced Proinflammatory
Cytokines and NO Production in BV2
Cells
Activated microglia release various pro-inﬂammatory cytokines,
chemokines, NO, superoxide (Shao et al., 2013). We then
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FIGURE 5 | Extracellular-signal-regulated kinase (ERK) pathway is involved in IL-1β and NO releases by U46619 in BV2 cells. (A) The experimental
design and procedure. First, BV2 cells were treated by U46619 (10 μM) for 24 h with or without U0126 (10 μM, 30 min) pretreatment, and the conditioned media
were collected and applied to SH-SY5Y cells. After 24 h incubation, effects on SH-SY5Y cells were assessed either by CCK-8 viability assay or microscopy. (B) The
viability of SH-SY5Y cells under various treatment conditions was analyzed by CCK-8 assay; and (C) cells were also observed by microscopy. (D) The effect of
U0126 on U46619-induced release of IL-1β in BV2 cells. (E) The effect of U0126 on U46619-induced release of NO from BV2 cells. Bar = 100μm (Data were
normalized against the vehicle-treated group. Data were presented as mean ± SEM.∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001, by one-way ANOVA followed by post
hoc Tukey’s test).
assessed whether TP activation by U46619 could up-regulate
cytokine and NO production. Indeed, U46619 largely enhanced
transcription of IL1-β, IL-6, and iNOS at mRNA levels
(Figures 4A–C). Then, we detected IL1-β and NO levels
in conditioned medium from BV2 cells. Correspondingly,
a signiﬁcant increase in protein levels of IL1-β had been
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FIGURE 6 | U46619 stimulates ERK activation in BV2 cells. (A) Dose-dependent effects of U46619 (0.1–10 μM, 15 min) on ERK activation in BV2 cells.
(B) Time-dependent effects of U46619 (1 μM, 10–60 min) on ERK activation in BV2 cells. (C) The effect of TP inhibitor SQ29548 (1 μM) on U46619-induced ERK
activation in BV2 cells. (D) The effect of MEK inhibitor U0126 (10 μM) on U46619-induced ERK activation in BV2 cells (The total ERK1/2 and p-ERK1/2 bands were
scanned and quantified. The p-ERK1/2 protein levels were normalized to total ERK1/2 protein levels. The basal levels in the vehicle-treated cells were assigned a
value of 1.0. The data are expressed as the mean ± SEM. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001, ∗∗∗∗P < 0.0001 by one-way ANOVA followed by post hoc Tukey’s
test).
detected after U46619 stimulation (Figure 4D). Pretreatment
with TP antagonist SQ29548 (30 min) markedly attenuated
IL1-β release (Figure 4D). Furthermore, U46619 stimulated
an increase of extracellular NO in the conditioned medium,
while SQ29548 treatment signiﬁcantly reduced NO levels
(Figure 4E). In sum, these results suggested that TP activation
could promote proinﬂammatory factors production and
stimulate neuroinﬂammation, which may explain the reduction
of SH-SY5Y cell survival in the above indirect co-culture
experiment.
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FIGURE 7 | The effects of TP regulation on ERK activation in primary microglia. (A) Time-dependent ERK activation by U46619 (1 μM, 5–45 min) in primary
microglia. (B) Effect of SQ29548 (1 μM, 30 min) and U0126 (10 μM, 30 min) pretreatment on ERK activation by U46619. (C) The effect of SQ29548 (1 μM) or
U0126 (10 μM) on U46619-induced IL-1β release from primary microglia. After incubation with the indicated concentrations of U46619 for 24 h with or without
SQ29548 or U0126 pretreatment, IL-1β released from BV2 cells was measured by ELISA (Data were normalized against the vehicle-treated group. Data were
presented as mean ± SEM. ∗P < 0.05, ∗∗P < 0.01, by one-way ANOVA followed by post hoc Tukey’s test).
Extracellular-Signal-Regulated Kinase
(ERK) Pathway Mediated the Activation
of BV2 Microglia by TP Signaling
Activation of the mitogen-activated protein kinases (MAPK)
signaling cascade plays an important role in inﬂammation (Irving
and Bamford, 2002). The MAPK family comprises the stress-
activated protein kinases/c-Jun N-terminal kinases (SAPK/JNK),
the p38 MAPKs, and ERKs. Preliminary experiments had
pinpointed the involvement of ERK signaling under TP activation
(Honma et al., 2006; Tokue et al., 2009). On this basis, we
next investigated whether ERK pathway modulation could
aﬀect microglia-neuron interaction after TP activation, following
similar experiment design (Figure 5A). MEK inhibitor U0126
was used to block ERK activation. BV2 cell were pretreated
with U0126 at 10 μM for 30 min, and then stimulated with
10 μM U46619 for 24 h. Conditioned media were collected,
applied to SH-SY5Y cells and cultured for 24 h, and then the
eﬀects on SH-SY5Y cells were observed. Similar to the result
shown in Figure 3, U46619-treated conditioned medium from
BV2 decreased SH-SY5Y cell viability and induced marked
morphological changes, while pretreatment with U0126 partially
but signiﬁcantly attenuated the eﬀect of U46619 (Figures 5B,C).
DMEDmediums directly added with U46619 and U0126 did not
inﬂuence SH-SY5Y cell survival rate (Supplementary Figure S1).
Second, we tested whether ERK signaling was involved in IL-1β
and NO releases by U46619 in BV2 cells. The results showed
that TP activation by U46619 promoted IL-1β protein release
in conditioned medium from BV2 cells, while this stimulation
was partially but signiﬁcantly attenuated by U0126 pretreatment
(Figure 5D). Furthermore, U46619 stimulated an increase of
extracellular NO release in the conditioned medium, while
U0126 treatment signiﬁcantly reduced NO levels (Figure 5E).
Taken together, these results suggested that ERK pathway was
involved in IL-1β and NO release induced by U46619 in BV2
cells.
As we have demonstrated that ERKMAPK pathway mediated
the IL-1β and NO expression and neuronal toxicity by TP
activation, we continued to investigate in detail the dose and
temporal proﬁle of ERK phosphorylation stimulated by TP
agonist in BV2 cells. Indeed, U46619 caused a dose- and time-
dependent stimulation of ERK phosphorylation (Figures 6A,B).
Elevated ERK phosphorylation occurred after U46619 treatment
at a dose as low as 0.1 μM (Figure 6A) and maximum activation
was achieved within 10–15 min (Figure 6B), suggesting a
relatively rapid signal response. Consistently, this stimulation was
blocked by SQ29548 (1 μM, 30 min) and MEK inhibitor U0126
(10 μM, 30 min) prior to treatment with U46619 (1 μM, 15 min;
Figures 6C,D). These results demonstrated that TP signaling
could induce ERK activation in BV2 cells. As showed in Figure 5,
ERK pathway was involved in IL-1β and NO release induced by
U46619 in BV2 cells. Taken all together, these results supported
the notion that ERK pathway mediated the microglial activation
by TP agonist U46619.
ERK Pathway Mediated the Activation of
Primary Microglia by TP Signaling
We then tried to conﬁrm the results obtained from BV2 cell
lines in the primary microglia culture. Consistently U46619
caused a time-dependent stimulation of ERK phosphorylation in
primary microglia, with maximum response at 15–20 min after
treatment (Figure 7A). This stimulation could be blocked by TP
antagonist SQ29548 (1 μM, 30 min) and MEK inhibitor U0126
(10 μM, 30 min) prior to treatment with U46619 (Figure 7B).
Furthermore, TP activation by U46619 promoted IL1-β protein
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release into conditioned medium from the primary microglia
culture, whereas this stimulation was partially attenuated by
U0126 pretreatment or completely by SQ29548 (Figure 7C).
In sum, these results conﬁrmed a physiological role of TP in
microglia activation, in which ERK pathway played a signiﬁcant
role.
DISCUSSION
In the present study, using a well-recognized tMCAO mouse
model, we demonstrated that ischemia-reperfusion enhanced
TP expression in ipsilateral brain tissue. Immunoﬂuorescence
staining revealed that both primary rat microglia and BV2 cells
expressed the TP, which was predominantly localized in the
plasma membrane. In addition, TP agonist U46619 enhanced
IL-1β, IL-6, iNOS mRNA expression and IL-1β, NO release in
microglia. The proinﬂammatory potential of TP was mediated
through the ERK phosphorylation. Together these data have
suggested that stimulation of TP signaling plays an important role
in regulation of microglia activation.
The amount of TXA2 is increased dramatically in the central
nervous system under pathologic conditions including CI. In
fact, activated microglia cells are the principal source of brain-
derived TXA2 (Fisher, 1993). On the other hand, TP level was
up-regulated in brain tissues under pathology conditions such
as subarachnoid hemorrhage (Ansar et al., 2010). In our study,
we demonstrated for the ﬁrst time that ischemia-reperfusion
increased the TP expression in ipsilateral brain tissue. We
also showed that microglia expressed the TP. Thus, after CI,
a robust activation of microglia may cause large amount of
TXA2 secretion, leading to activation of TP on cells around the
TXA2-producing cells via autocrine or paracrine mechanisms
and ﬁnally form a vicious circle. Therefore, an investigation of
the physiological roles of TP in microglia inﬂammation will help
in providing new targets for the prevention and treatment of CI.
IL-1β contributes to the regulation of various chronic and
acute inﬂammatory responses in central nervous system diseases.
Its expression exhibited a biphasic pattern in tMCAO models
with a ﬁrst peak at 1 h after reperfusion and a second peak at
6–24 h (Ceulemans et al., 2010). Activated microglia account
for the larger part of IL-1β production in early stage (Utagawa
et al., 2008). IL-1β stimulates microglia and astrocytes, leading
to an up-regulation of genes encoding for more neurotoxic
mediators and inducing a spellbound damaging cycle. Previous
studies have demonstrated that overexpression of IL-1β could
exacerbate ischemic brain damage, while deﬁciency in IL-1β
has been reported to decrease infarct volume. Caughey et al.
(1997) found that TXA2 was an important paracrine or autocrine
facilitator of TNF-α and IL-1β production in activated human
monocytes. Microglia are the resident macrophages in central
nervous system. Given those functional TP receptors in activated
monocytes, we examined whether TP activation by U46619 could
up-regulate IL-1β production in microglia. Consistent with the
study in monocytes, we found that U46619 enhanced IL-1β
mRNA expression and protein release in microglia, which could
be blocked by TP antagonist or ERK inhibition.
NO is an important biomolecule and appears to be mainly
toxic in the case of CI (Lakhan et al., 2009). NO can react with
superoxide to form peroxynitrite, its reactive metabolite, leading
to cellular toxicity. Nitric oxide synthase (NOS) catalyzes the
synthesis of NO. However, microglia only express the inducible
form of NOS (iNOS; Yenari et al., 2010). After CI, activated
microglia enhance the NO production by up-regulating the
expression of iNOS mRNA and protein, thus contributing to
ischemic brain damage. Inhibition of iNOS with aminoguanidine
could reduce infarct volume by about 30% (Iadecola et al., 1995),
while iNOS-null mice have shown smaller infarct volume and
better neurologic outcomes (Zhao et al., 2000). He et al. (2013)
reported that TP activation by I-BOP and U46619 induced an
aberrant expression of iNOS in human umbilical vein endothelial
cells. Mitsumori et al. (2011) found that TP stimulation in
the striatum locally facilitated dopamine overﬂow evoked by
synaptic inputs via NO synthesis in endothelial cells. Lubrano
et al. (2008) demonstrated that TP activation enhanced NO
production in microvascular endothelium. In the present study,
we discovered that U46619 enhanced iNOS mRNA expression
and NO release in microglia cells, which could also be attenuated
by TP antagonist and ERK inhibitor.
The MAPK family is comprised of the JNK, p38, and ERK
(Irving and Bamford, 2002). All three pathways have been
described in activated microglia. Various kinds of stimuli, such
as lipopolysaccharide (LPS), alpha-synuclein, and amyloid-beta
(Aβ), are able to activate MAPK signaling pathways in microglia.
In our study, we have focused on the ERK signaling in regulation
of microglia. There are a number of literatures in support of
such roles of ERK. Kitagawa et al. (1999) revealed that ischemia
enhanced ERK expression in brain. Pharmacological inhibition
of the ERK signaling pathways improved outcomes in ischemia-
reperfusion mouse model (Alessandrini et al., 1999). Previous
studies have shown that LPS promoted TNF-α, IL-1β, and IL-
6 production in microglia by ERK signaling pathway (Carter
et al., 1999; Caivano and Cohen, 2000; Kim et al., 2004). Chan
et al. (2001) found that all three pathways (JNK, p38, and ERK)
played important regulatory roles in regulation of iNOS and NO
expression in mononuclear phagocytes. The ERK pathway may
regulate inﬂammation mainly through its eﬀects on poly (ADP-
ribose) polymerase-1 (PARP-1) activation (Kauppinen et al.,
2006). PARP-1 is an abundant nuclear enzyme associated with
both transcriptional regulation and DNA repair. It can interact
with other proinﬂammatory transcription factors to regulate the
inﬂammatory responses in microglia, including NF-κB, AP-1, etc.
(Ha et al., 2002; Yenari et al., 2010). PARP-1 inhibition as well
as depletion prevents microglial morphological transformation,
secretion of cytokines, migration to lesion site (Yenari et al.,
2010).
In our study, we provided evidence to link TP signaling
and ERK activation in the microglial cells. This conﬁrms with
several previous studies demonstrating that TP can activate ERK
signaling pathway in other cell types. Tokue et al. (2009) found
that TP promoted phosphoinositide hydrolysis, phosphorylation
of ERK, and IL-6 production. Honma et al. (2006) revealed
that stimulation of TP causes the glial morphological change
with proliferation mainly through ERK signaling pathway.
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In oligodendrocytes, U46619 was found to increase CREB
and ERK phosphorylation, contributing to cell proliferation,
survival and gene expression (Lin et al., 2005). Our data
showed that TP activation by U46619 promoted IL-1β protein
release in microglia, and this stimulation could be signiﬁcantly
attenuated by U0126 pretreatment. From the level of attenuation,
ERK pathway was mostly responsible for TP-mediated IL-1β
production in microglia. However, it is likely that other signaling
pathways could be involved, probably in other cell context.
Indeed, Obara et al. (2005) reported that TXA2 enhances the IL-
6 biosynthesis through the PKA/p38 MAPK/CREB pathway in
1321N1 cells. Zhang et al. (2011) found that TP enhanced protein
synthesis in vascular smooth muscle cells via AMP-activated
kinase pathway.
There are some limitations in this study. Firstly, although
we have demonstrated the involvement of ERK pathway
in TP mediated IL-1β and NO production in BV2 cells,
the speciﬁc signaling pathways downstream of ERK are
still poorly understood. The ERK pathway may regulate
inﬂammation through its eﬀects on PARP-1. Whether
PARP-1 activation associates with TP mediated microglia
inﬂammation still require further research. Secondly, ERK
pathway was only partially responsible for TP mediated IL-
1β production in BV2 and primary microglia. The other
related signaling pathways need to be evaluated. Thirdly,
ischemia-reperfusion enhanced TP expression in ipsilateral
brain tissue. However, we only focused on microglia but
the role of other types of cells in the brain with regard
to elevated TP expression could not be ruled out. We also
found that the primary astrocytes express the TP by Western
blot (Supplementary Figure S2), which warrants further
investigation.
CONCLUSION
We showed that TP activation increased the expression of
proinﬂammatory cytokines including IL-1β and NO, via ERK
signaling pathway in microglia. Our results have suggested a
novel physiological role of TP in microglia, which is plausibly a
druggable target for the management of neurological diseases like
CI.
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Figure S1 | U46619, SQ29548, and U0126 treatment did not induce
cytotoxicity in SH-SY5Y cells. U46619, SQ29548, U0126, U46619 plus
SQ29548 and U46619 plus U0126 were directly added to DMED medium and
placed in incubator for 24 h, and then these mediums were applied to neuronal
SH-SY5Y cells that had been seeded in 96-well plates. After 24 h, CCK-8 was
used to evaluate the changes in SH-SY5Y cell viability.
Figure S2 | Expression of TP in primary astrocytes. Primary astrocytes were
prepared from 24 h neonatal SD rat brains and then cultivated in DMEM/F12
supplemented with 10% fetal calf serum, 1% penicillin/streptomycin. The
expression of TP in primary astrocytes was detected by Western blot.
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